Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Sarah Brown(University of Leeds), Neil Rabin(University College London), Louise Flanagan(University of Leeds), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Faith E. Davies(NYU Langone Health), Stephen Hawkins(Children's Hospital Colorado), Ceri Bygrave(Cardiff and Vale University Health Board), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Holger W. Auner(University Hospital of Lausanne), Debbie Sherratt(University of Leeds), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Samantha Hinsley(University of Leeds), Gareth J. Morgan(Hywel Dda University Health Board), Catherine Williams(University College Hospital), Ruth M. de Tute(St James's University Hospital), Jamie Cavenagh(St Bartholomew's Hospital), James Croft(Institute of Cancer Research)
Cited by 15
Related Papers
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k